TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03967314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TLIP block group (group T)
Description: In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration group (group W)
Description: In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
Study: NCT02537860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo at T11 and L3
Description: Two injections that contain saline are performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block injections between T11 and L3
Description: Five anesthetic injections are done

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Herniorrhaphy
Description: Unilateral inguinal hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Herniorrhaphy
Description: Unilateral inguinal hernia repair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) fentanyl
Description: Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) fentanyl
Description: Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Each patient will receive 75 mg bupivacaine during PVB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Each patient will receive 75 mg bupivacaine during PVB
Study: NCT02484261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages \>14 years
Study: NCT03666767

Intervention type: OTHER
Intervention: Comparisons will be made between LMICs and HICs
Description: Countries will be defined as low, middle or high-income using the World Bank classification.

Intervention type: OTHER
Intervention: Comparisons will be made between LMICs and HICs
Description: Countries will be defined as low, middle or high-income using the World Bank classification.

Intervention type: OTHER
Intervention: Comparisons will be made between LMICs and HICs
Description: Countries will be defined as low, middle or high-income using the World Bank classification.

Intervention type: OTHER
Intervention: Comparisons will be made between LMICs and HICs
Description: Countries will be defined as low, middle or high-income using the World Bank classification.

Intervention type: OTHER
Intervention: Comparisons will be made between LMICs and HICs
Description: Countries will be defined as low, middle or high-income using the World Bank classification.

Intervention type: OTHER
Intervention: Comparisons will be made between LMICs and HICs
Description: Countries will be defined as low, middle or high-income using the World Bank classification.

Intervention type: OTHER
Intervention: Comparisons will be made between LMICs and HICs
Description: Countries will be defined as low, middle or high-income using the World Bank classification.
Study: NCT02273973

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
Study: NCT01676116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
Study: NCT01064089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSP990
Study: NCT02207387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect
Description: Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect
Description: Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
Study: NCT00428298

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take two 500 mg capsules twice daily for 16 weeks.
Study: NCT01901263

Intervention type: BEHAVIORAL
Intervention: patients with alzheimer's disease
Description: the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
Study: NCT02261389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm B, tumor markers assessment
Description: Tumor markers assessment every three months through the study or until disease recurrence
Study: NCT01836380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Study: NCT04188080

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarlsberg Cheese
Description: Oral daily intake of Jarlsberg cheese
Study: NCT02207387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Study: NCT03887910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
Study: NCT03144050

Intervention type: DEVICE
Intervention: SFDI Imaging
Description: Imaging with SFDI device

Intervention type: DEVICE
Intervention: SFDI Imaging
Description: Imaging with SFDI device

Intervention type: DEVICE
Intervention: SFDI Imaging
Description: Imaging with SFDI device

Intervention type: DEVICE
Intervention: SFDI Imaging
Description: Imaging with SFDI device

Intervention type: DEVICE
Intervention: SFDI Imaging
Description: Imaging with SFDI device

Intervention type: DEVICE
Intervention: SFDI Imaging
Description: Imaging with SFDI device
Study: NCT03347487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimuation system implantation
Description: All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
Study: NCT02543489

Intervention type: DEVICE
Group type: OTHER
Intervention: Flex IM rod
Study: NCT02965859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metacavir Enteric-coated Capsules 80mg
Description: Metacavir Enteric-coated Capsules 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules 160mg
Description: Metacavir Enteric-coated Capsules 160mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules 320mg
Description: Metacavir Enteric-coated Capsules 320mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules 320mg
Description: Metacavir Enteric-coated Capsules 320mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metacavir Enteric-coated Capsules Placebo 240mg
Description: Metacavir Enteric-coated Capsules Placebo 240mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules Placebo 160mg
Description: Metacavir Enteric-coated Capsules Placebo 160mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules Placebo 320mg
Description: Metacavir Enteric-coated Capsules Placebo 320mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metacavir Enteric-coated Capsules Placebo 320mg
Description: Metacavir Enteric-coated Capsules Placebo 320mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil Capsule10mg
Description: Adefovir Dipivoxil Capsule10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil Capsule Placebo 10mg
Description: Adefovir Dipivoxil Capsule Placebo 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil Capsule Placebo 10mg
Description: Adefovir Dipivoxil Capsule Placebo 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adefovir Dipivoxil Capsule Placebo 10mg
Description: Adefovir Dipivoxil Capsule Placebo 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adefovir Dipivoxil Capsule Placebo 10mg
Description: Adefovir Dipivoxil Capsule Placebo 10mg
Study: NCT05167474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breast milk smell
Description: yenidoğanlara fototerapi tedavisi esnasında anne sütü kokusu uygulanmıştır.
Study: NCT04653363

Intervention type: OTHER
Intervention: assessments
Description: All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.

Intervention type: OTHER
Intervention: assessments
Description: All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.

Intervention type: OTHER
Intervention: assessments
Description: All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.
Study: NCT01964053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATCH intervention
Description: The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
Study: NCT03264339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Step Program
Description: The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
Study: NCT04521426

Intervention type: OTHER
Intervention: No other than standard care
Description: No other than standard care.
Study: NCT02207387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Study: NCT02652819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04521426

Intervention type: OTHER
Intervention: No other than standard care
Description: No other than standard care.

Intervention type: OTHER
Intervention: No other than standard care
Description: No other than standard care.
Study: NCT00833209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET (withdrawal)
Description: 3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imaging
Description: 2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imaging
Description: 1 MRI ; Iowa Gambling Task test and questionnaires.
Study: NCT03575650

Intervention type: OTHER
Intervention: Cardiac imaging modalities
Description: Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
Study: NCT03364192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Health Coaching
Description: Veterans Health Administration variation of integrative health coaching.
Study: NCT04545307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis
Description: The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
Study: NCT03906695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: oral decitabine 5mg + cedazuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: oral decitabine 5mg + cedazuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: oral decitabine 10mg + cedazuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: oral decitabine 20mg + cedazuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: oral decitabine 10mg + cedazuridine
Study: NCT01887210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB Gaming Adherence Intervention
Description: Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Smart pill bottle cap and mobile phone but no game
Study: NCT02586207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (MK-3475)
Description: 200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 70 Gy fractionated over 35 days
Study: NCT01998646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4058
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4058
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4058
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT02900677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical and nutrition program
Description: 6 education programs with physical enhancement and nutrition related information for 12 weeks
Study: NCT00680732

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplements (MMS)
Description: Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplements (MMS)
Description: Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Description: Iron 60 mg and folic acid 400 mcg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Description: Iron 60 mg and folic acid 400 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Description: Tablets 100 mg of chloroquine base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Description: Tablets 100 mg of chloroquine base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxyne-pyrimethamine (SP)
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxyne-pyrimethamine (SP)
Description: Tablets
Study: NCT00687050

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: peroral high-caloric supplemental nutrition
Description: HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: peroral supplemental nutrition
Description: Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
Study: NCT01388400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional occupational therapy
Description: upper limb exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video capture virtual reality
Description: virtual reality delivered uppe limb exercises
Study: NCT02551172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1105
Description: Rosuvastatin + Omega-3-acids ethyl esters

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HGP0816
Description: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816
Description: Rosuvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HCP1105
Description: Soybean Oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of HGP0816
Description: Exclusion of Rosuvastatin in HGP0816
Study: NCT04374864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Anti diabetic